David Hahn
Genentech, Inc., A Member of the Roche Group, 1 DNA Way, South San Francisco, CA 94080, USA
Articles
Risk-Based Predictive Stability–An Industry Perspective
Fenghe Qiu;Yan Wu;David Hahn;Megan McMahon;Rachel Orr;Debra Webb;Elke Debie;Lois Sechler;Helen Williams;Dennis Stephens;Cherokee Hoaglund Hyzer
March 2nd 2017A survey on risk-based predictive stability tools reveals how pharma companies are leveraging advanced stability approaches throughout the drug development process.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: August 21st 2024 | Updated: December 30th 2024
Pharmaceutical Technology Editorial Advisory Board
Published: November 25th 2024 | Updated: December 30th 2024
Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics
Published: December 20th 2024 | Updated: December 30th 2024
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Published: February 23rd 2024 | Updated: December 30th 2024
Europa Perspectives: Helping to Navigate the Regulatory System
